September 2021- Entera presented "A Six-month Phase 2 Study of Oral PTH in Post Menopausal Women with Low Bone Mass – An Interim Three-Month Analysis" at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in San Diego, California. Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue that leads to decreased bone strength and increased risk of fracture. Teriparatide [hPTH(1-34)] for injection (Forteo®) is an osteoanabolic treatment that has been shown to reduce the risk of vertebral fractures by 65 to 80%. Injections deter many older osteoporotic patients from either starting or continuing the drug, contributing to the treatment gap in high-risk patients. An oral formulation of hPTH(1-34) (PTH) with adequate bioavailability, and similar safety and effects on BMD may address this unmet clinical need.